Marie-Claude Morice, Institut Cardiovasculaire Paris Sud Joins Tryton Medical’s First-in-Man Study

Nov. 29, 2006 – Newton, MA, U.S.A. –November 30, 2006– Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that the Institut Cardiovasculaire Paris Sud joined Tryton Medical’s First-in-Man (FIM) Study and have successfully used Tryton’s Side-Branch Stent without in-hospital complications in two patients. “Tryton’s Side-Branch Stent provides a robust approach to definitively treat bifurcation lesions, especially the lesions which would be inappropriate for a provisional strategy,” said Marie-Claude Morice, M.D., Institut Cardiovasculaire Paris Sud.

“Tryton Medical is pleased that Institut Cardiovasculaire Paris Sud’s Drs. Morice, LeFevre and Louvard have joined the Tryton FIM Study,” said H. Richard Davis, CTO, Tryton Medical, Inc. “This renowned group, in addition to being a leading French Interventional center, is distinguished worldwide for its work in bifurcation stenting,” Davis added.

“The initial 20 FIM patients had complex bifurcation lesions and they were definitively treated with 100% procedural and clinical success,” said Aaron V. Kaplan, M.D., F.A.C.C. Associate Professor of Medicine (Cardiology) at Dartmouth Medical School and co-Founder of Tryton Medical, Inc. “These results demonstrate how Tryton Medical’s Side-Branch Stent can treat the most challenging bifurcation lesions in conjunction with a standard workhorse stent and standard techniques (6 Fr. Guide Catheters, etc.) to obtain superb results,” Dr. Kaplan added.

Tryton’s First-In-Man Study is a multi-center clinical trial evaluating the safety of Tryton’s Side-Branch Stent in the treatment of coronary bifurcation lesions. The Study is also being performed the HELIOS Heart Center/Siegburg, Germany under the direction of Prof. Eberhard Grube, Principal Investigator, and at the Thoraxcenter Rotterdam (Prof. Patrick Serruys, Principal Investigator). During this study, Tryton’s stents have been used in conjunction with a standard workhorse stent to treat a wide spectrum of bifurcation lesions with superior angiographic results and without major adverse cardiac events. 540,000 bifurcation coronary lesions are sub-optimally treated every year as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent– leaving the side branch vulnerable to thrombosis and restenosis.

To see pictures of pre and post-angiographic results that show the Tryton Side-Branch Stent benefits, visit www.TrytonMedical.com and click on “Save the Side Branch”.

About Tryton Medical, Inc.

Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution is commercially available for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent– leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.

Tryton Medical’s Side-Branch Stent™ has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions while eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact Joe Romano, Partner, HighGround, Inc. at +1 781-279-1320 x 208, jromano@highgroundinc.com or visit www.TrytonMedical.com
# # #

— End —